The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats

Toxicology

Volumn 191, Issue 2-3, 2003, Pages 159-167

  Pfister, Thomas ^a   Atzpodien, Elke ^a   Bauss, Frieder ^b,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bisphosphonates; Ibandronate; Nephrotoxicity; Renal safety; Zoledronate

Indexed keywords

IBANDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; GLUTATHIONE TRANSFERASE; IMIDAZOLE DERIVATIVE; LACTATE DEHYDROGENASE; N ACETYLGLUCOSAMINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; INCIDENCE; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; PATHOLOGY; URINE; WISTAR RAT;

ACETYLGLUCOSAMINE; ANIMALS; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE TRANSFERASE; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; L-LACTATE DEHYDROGENASE; RATS; RATS, WISTAR; UREA;

EID: 0142057014     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(03)00257-9     Document Type: Article

References (20)

1. Adami S., Zamperlan N. Adverse effects of bisphosphonates. Drug Saf. 14:1996;158-170.
2. Alden C.L., Parker R.D., Eastman D.F. Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol. Pathol. 17:1989;27-32.
3. Alden C.L., Burns J.L., Parker R.D., Englehart J.L., Dennis V.W. Characterization of the early ultrastructural and biochemical events occurring in dichloromethane diphosphonate nephrotoxicity. Toxicol. Pathol. 18:1990;661-666.
4. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol. 4:(S11):2001;49-53.
5. Bounameaux H.M., Schifferli J., Montani J.P., Jung A., Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet. 1:1983;471.
6. Cal J.C., Daley-Yates P.T. Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology. 65:1990;179-197.
7. Cal J.C., Cockshott A., Daley-Yates P.T. Experimental acute renal failure induced by 3-amino-1-hydroxyproylidene-1,1-bisphosphonate in rodents. Bach P.H., Gregg N.J., Wiks M.F., Delacruz L. Nephrotoxicity. Mechanism, Early Diagnosis, and Therapeutic Management. 1991;43-48 Marcel Dekker, New York.
8. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 2000;Academic Press.
9. Green J.R., Seltenmeyer Y., Jaeggi K.A., Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol. Toxicol. 80:1997;225-230.
10. Hillner B.E., Ingle J.N., Berenson J.R., Janjan N.A., Albain K.S., Lipton A., Yee G., Biermann J.S., Chlebowski R.T., Pfister D.G. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18:2000;1378-1391.
11. Janssen van Doorn K., Neyns B., Van der Niepen P., Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 89:2001;467-468.
12. Markowitz G.S., Fine P.L., Stack J.I., Kunis C.L., Radhakrishnan J., Palecki W., Park J., Nasr S.H., Hoh S., Siegel D.S., D'Agatti V.D. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 64:2003;281-289.
13. Menssen H.D., Sakalova A., Fontana A., Herrmann Z., Boewer C., Facon T., Lichinitser M.R., Singer C.R.J., Euller-Ziegler L., Wetterwald M., Fiere D., Hrubisko M., Thiel E., Delmas P.D. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J. Clin. Oncol. 20:2002;2353-2359.
14. Okazaki A., Sakai H., Matsuzawa T., Perkin C.J., East P.W. Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats. J. Toxicol. Sci. 20:(S1):1995;15-26.
15. Okazaki A., Sakai H., Matsuzawa T., Perkin C.J., East P.W. Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in beagle dogs. J. Toxicol. Sci. 20:(Suppl. I):1995;27-36.
16. O'Sullivan T.L., Akbari A., Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Renal Fail. 16:1994;767-773.
17. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelsteadt J., Hussein M., Coleman R.E., Reitsma D.J., Seaman J.J., Chen B.L., Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double-blind, comparative trial. Cancer J. 7:2001;377-387.
18. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94:2002;1458-1468.
19. Zazgornik J., Grafinger P., Biesenbach G., Hubmann R., Fridrik M. Acute renal failure and alendronate. Nephrol. Dial. Transplant. 12:1997;2797-2798.
20. Zojer N., Keck A.V., Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 21:1999;389-406.